Platelet aggregation, dyslipoproteinemia and polyunsaturated fatty acids

Platelet aggregation, dyslipoproteinemia and polyunsaturated fatty acids

The article reviews the trials on the association between increased functional activity of platelets and platelet membrane polyunsaturated fatty acids (PUFA), PUFA in serum lipoprotein phospholipids, and dyslipoproteinemia (DLP) type and severity. Platelet structural and functional disturbances, oft...

Full description

Bibliographic Details
Main Authors: E. I. Sokolov, V. A. Metelskaya, N. V. Perova, G. N. Shchukina, V. M. Fomina
Format: Article
Language:Russian
Published: «SILICEA-POLIGRAF» LLC 2006-10-01
Series:Кардиоваскулярная терапия и профилактика
Subjects:
platelets
aggregation
dyslipoproteinemia
polyunsaturated fatty acids
arachidonic acid
Online Access:https://cardiovascular.elpub.ru/jour/article/view/1324
id doaj-d9719f1feb514d5eb68cfefc27453dfd
record_format Article
spelling doaj-d9719f1feb514d5eb68cfefc27453dfd2021-07-28T13:50:43Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252006-10-015587931034Platelet aggregation, dyslipoproteinemia and polyunsaturated fatty acidsE. I. Sokolov0V. A. Metelskaya1N. V. Perova2G. N. Shchukina3V. M. Fomina4Moscow State Medico-Stomatological University. MoscowState Research Center for Preventive Medicine, State Federal Agency for Health and Social Development. MoscowState Research Center for Preventive Medicine, State Federal Agency for Health and Social Development. MoscowMoscow State Medico-Stomatological University. MoscowMoscow State Medico-Stomatological University. MoscowThe article reviews the trials on the association between increased functional activity of platelets and platelet membrane polyunsaturated fatty acids (PUFA), PUFA in serum lipoprotein phospholipids, and dyslipoproteinemia (DLP) type and severity. Platelet structural and functional disturbances, often accompanying DLP and influenced by its type, affect platelet aggregation – via platelet membrane lipid modification, as well as via modified synthesis of platelet functional activity modulators (e.g., TxA2 ). Possible approaches to platelet hyperaggregation correction are discussed, including membrane lipid modulation via lipoprotein profile normalization during pharmaceutical and non-pharmaceutical treatment.https://cardiovascular.elpub.ru/jour/article/view/1324plateletsaggregationdyslipoproteinemiapolyunsaturated fatty acidsarachidonic acid
collection DOAJ
language Russian
format Article
sources DOAJ
author E. I. Sokolov
V. A. Metelskaya
N. V. Perova
G. N. Shchukina
V. M. Fomina
spellingShingle E. I. Sokolov
V. A. Metelskaya
N. V. Perova
G. N. Shchukina
V. M. Fomina
Platelet aggregation, dyslipoproteinemia and polyunsaturated fatty acids
Кардиоваскулярная терапия и профилактика
platelets
aggregation
dyslipoproteinemia
polyunsaturated fatty acids
arachidonic acid
author_facet E. I. Sokolov
V. A. Metelskaya
N. V. Perova
G. N. Shchukina
V. M. Fomina
author_sort E. I. Sokolov
title Platelet aggregation, dyslipoproteinemia and polyunsaturated fatty acids
title_short Platelet aggregation, dyslipoproteinemia and polyunsaturated fatty acids
title_full Platelet aggregation, dyslipoproteinemia and polyunsaturated fatty acids
title_fullStr Platelet aggregation, dyslipoproteinemia and polyunsaturated fatty acids
title_full_unstemmed Platelet aggregation, dyslipoproteinemia and polyunsaturated fatty acids
title_sort platelet aggregation, dyslipoproteinemia and polyunsaturated fatty acids
publisher «SILICEA-POLIGRAF» LLC
series Кардиоваскулярная терапия и профилактика
issn 1728-8800
2619-0125
publishDate 2006-10-01
description The article reviews the trials on the association between increased functional activity of platelets and platelet membrane polyunsaturated fatty acids (PUFA), PUFA in serum lipoprotein phospholipids, and dyslipoproteinemia (DLP) type and severity. Platelet structural and functional disturbances, often accompanying DLP and influenced by its type, affect platelet aggregation – via platelet membrane lipid modification, as well as via modified synthesis of platelet functional activity modulators (e.g., TxA2 ). Possible approaches to platelet hyperaggregation correction are discussed, including membrane lipid modulation via lipoprotein profile normalization during pharmaceutical and non-pharmaceutical treatment.
topic platelets
aggregation
dyslipoproteinemia
polyunsaturated fatty acids
arachidonic acid
url https://cardiovascular.elpub.ru/jour/article/view/1324
work_keys_str_mv AT eisokolov plateletaggregationdyslipoproteinemiaandpolyunsaturatedfattyacids
AT vametelskaya plateletaggregationdyslipoproteinemiaandpolyunsaturatedfattyacids
AT nvperova plateletaggregationdyslipoproteinemiaandpolyunsaturatedfattyacids
AT gnshchukina plateletaggregationdyslipoproteinemiaandpolyunsaturatedfattyacids
AT vmfomina plateletaggregationdyslipoproteinemiaandpolyunsaturatedfattyacids
_version_ 1721271390179426304

Similar Items